Another Ranbaxy Drug Plant Fails FDA Test
The FDA prohibited Ranbaxy's Toansa, India, site from manufacturing active pharmaceutical ingredients for FDA-regulated products after officials uncovered "significant" violations of U.S.-promulgated manufacturing practices meant to ensure drug safety.
Topping the list was Ranbaxy employees’ practice of retesting raw materials, intermediate drug products and finished APIs that failed to meet specifications until...
Already a subscriber? Click here to login